Surgical simulation steps into a new phase in ophthalmology

Tern plc

In the niche but technically demanding world of ophthalmology, a new approach to training is gaining ground. The traditional reliance on live surgical observation and supervised repetition is being supplemented, and in some cases, pre-empted, by immersive extended reality. At the centre of this evolution is a structured rollout model that reframes simulation as a progressive system of implementation.

Fundamental XR has laid out a clear, phased framework for XR adoption, beginning with pilot testing and moving deliberately through infrastructure deployment, staff onboarding, content calibration, and outcome tracking. This matters because while extended reality has been circulating in healthcare discussions for years, what has often been missing is a replicable model for institutional uptake, something that works beyond a showcase or demo setting.

What makes this opportunity distinctive is that it bypasses much of the hype surrounding general-use XR platforms. Instead, it targets a clear pain point, surgical training bottlenecks, with a solution that is already seeing traction across professional institutions.

Developing and maintaining specialty-specific content, adapting to new surgical techniques and staying aligned with evolving training standards all require sustained investment. But these same factors create defensible barriers to entry. In fields like ophthalmology, where each device or procedure has unique requirements, the demand for high-fidelity simulation remains acute, and unlikely to be met by generalist solutions.

More importantly, this model may not stay confined to one field. If the implementation roadmap proves successful in ophthalmology, there is a clear logic to extending it into other surgical specialities.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines joins 2026 UK AI Index

Talking Medicines joins the UK AI Index 2026, confirming its growing role in data-driven healthcare strategy.

AI in Healthcare 2025

In 2025, AI began reshaping healthcare delivery and marketing with practical applications, signalling a maturing investment landscape.

Talking Medicines targets messaging risk in pharma brand strategy

Talking Medicines reduces messaging risk for pharma brands by measuring real-time HCP response.

Agentless security for untouchable IoT devices

Agentless IoT security provides identity‑driven protection for devices that cannot be directly managed, turning blind spots into governed assets.

Virtual reality surgical training wins industry attention with scalable model

A new VR training solution backed by Orbis and Fundamental XR is gaining global traction by tackling real-world gaps in surgical education.

Tern Plc publishes presentations from Device Authority and Talking Medicines investor event

Tern Plc has released copies of the presentations delivered by portfolio companies Device Authority and Talking Medicines during its recent online investor presentation and Q&A session.

Search

Search